Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Diagonal Bio AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.025 |
52 Week High | SEK 0.62 |
52 Week Low | SEK 0.022 |
Beta | 0.51 |
11 Month Change | -7.97% |
3 Month Change | -61.80% |
1 Year Change | -94.97% |
33 Year Change | -99.85% |
5 Year Change | n/a |
Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
DIABIO | SE Biotechs | SE Market | |
---|---|---|---|
7D | -8.0% | -2.4% | -4.3% |
1Y | -95.0% | 18.0% | 12.6% |
Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned 18.1% over the past year.
Return vs Market: DIABIO underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
DIABIO volatility | |
---|---|
DIABIO Average Weekly Movement | 24.3% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: DIABIO's share price has been volatile over the past 3 months.
Volatility Over Time: DIABIO's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 4 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
DIABIO fundamental statistics | |
---|---|
Market cap | SEK 10.18m |
Earnings (TTM) | -SEK 10.97m |
Revenue (TTM) | SEK 2.37m |
4.3x
P/S Ratio-0.9x
P/E RatioIs DIABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DIABIO income statement (TTM) | |
---|---|
Revenue | SEK 2.37m |
Cost of Revenue | SEK 18.00k |
Gross Profit | SEK 2.35m |
Other Expenses | SEK 13.33m |
Earnings | -SEK 10.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | -0.027 |
Gross Margin | 99.24% |
Net Profit Margin | -462.88% |
Debt/Equity Ratio | 0% |
How did DIABIO perform over the long term?
See historical performance and comparison